

# HOTH THERAPEUTIC ANNOUNCES THAT IT HAS SUBMITTED ITS REQUEST TO AUSTRALIA ETHICS BOARD TO BEGIN CLINICAL TRIAL OF BIOLEXA FOR ATOPIC DERMATITIS

## STUDY TO DETERMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF TWICE DAILY APPLICATION OF TOPICAL BIOLEXA IN HEALTHY SUBJECTS AND PATIENTS WITH MILD TO MODERATE ATOPIC DERMATITIS

NEW YORK, Aug. 13, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has submitted for ethics approval in Australia for its planned Clinical study of its therapeutic BioLexa for Atopic Dermatitis. The ethics submission was made to the Bellberry Human Research Ethics Committee in Australia.



Hoth's proposed study will be a Randomised, Double-Blind, Vehicle Controlled, Sequential Group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis.

Mr. Robb Knie, Chief Executive Officer of Hoth, stated, "Thanks to the hard work of our team and CRO partner Novotech, this ethics submission is yet another important step in the Company's clinical development program."

BioLexa is a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis. The therapeutic offers a **non-corticosteroid** approach in treating atopic dermatitis.

### About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit [www.hoththerapeutics.com](http://www.hoththerapeutics.com).

### Forward-Looking Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

### Investor Contact:

Email: [investorrelations@hoththerapeutics.com](mailto:investorrelations@hoththerapeutics.com)

[www.hoththerapeutics.com](http://www.hoththerapeutics.com)

Phone: (678) 570-6791 LR Advisors LLC



View original content to download multimedia: <http://www.prnewswire.com/news-releases/hoth-therapeutic-announces-that-it-has-submitted-its-request-to-australia-ethics-board-to-begin-clinical-trial-of-biolexa-for-atopic-dermatitis-301111852.html>

SOURCE Hoth Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia